prednisone / Generic mfg. - LARVOL DELTA

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12) (ASH 2025) - P1/2 | "The study consists of three arms: Arm 1: Birelentinib + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6 cycles. Arm 2: Birelentinib + R-GemOx (rituximab, gemcitabine, oxaliplatin) for 8 cycles. Arm 3: Birelentinib + BR (rituximab, bendamustine) for 6 cycles...Pharmacokinetic analyses will be conducted as secondary objectives in both parts of the study. Patient enrollment for this study commenced in July 2025 and is currently ongoing."

Clinical • Combination therapy • P2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2

Convergence in age adjusted mortality rates and proportion of all deaths from COVID-19 among patients with hematologic malignancies, 2020-2024 (ASH 2025) - "One retrospective cohort study found no effect of immunosuppression with prednisone, tacrolimus, or mycophenolate mofetil on ventilation, in-hospital mortality or length of stay among hospitalized COVID-19 patients in one hospital system (Andersen et. There was a higher peak AAMR from COVID-19 as a proportion of all deaths in the general population during the heights of the COVID-19 pandemic (2020-2021) than among patients with HM as a share of all HM-associated deaths in the same period across all regions. The all-cause AAMR is higher at baseline among patients with HM, so the effect of COVID-19 may have been smaller in this population as a share of all deaths. Patients known to have HM may access care, take airborne precautions and vaccinate more regularly."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Solid Tumor

Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data (ASH 2025) - "All patients received at least 3 cycles of Pola-based regimens, with the vast majority administered Pola-R-CHP, consisting of polatuzumab vedotin (1.8 mg/kg, intravenous [IV], day 1); rituximab (375 mg/m², IV day 1); cyclophosphamide (750 mg/m², IV, day 1); doxorubicin (50 mg/m², IV, day 1); and prednisone (100 mg,oral, days 1–5), repeated every 21 days. Conclusion Our findings indicate that Pola-based regimens exhibit high response rates and favorable safety profiles in newly diagnosed DLBCL patients with high-risk features in real world settings. Prospective studies with larger cohorts are needed to further validate these observations."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD5 • CD79B • TP53

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review (ASH 2025) - P3 | "Introduction: The phase III POLARIX study (NCT03274492) demonstrated the superiority of Polatuzumab vedotin (Pola) combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) over R-CHOP, marking the first major advancement in over 20 years in first-line (1L) diffuse large B-cell lymphoma (DLBCL). This SLR analyzing currently available RWD addressing the safety and effectiveness of Pola-R-CHP for 1L DLBCL aligns with results from the POLARIX trial. Despite study and reporting heterogeneity, response rates and PFS are consistent, as are outcomes in patients older than 80 years, supporting the use of this regimen in patients with newly diagnosed DLBCL."

Clinical • Real-world • Real-world evidence • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma

Vincristine-induced neuropathy: Long term follow-up of lymphoma survivors treated with CHOP or dose-adjusted EPOCH chemotherapy (ASH 2025) - "Introduction: The incidence of Vincristine-induced neuropathy (VIN) occurs in up to 70% of non Hodgkin Lymphoma (NHL) survivors treated with front-line lymphoma regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and infusional dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), administered with or without rituximab (R) (Su et al., 2025). Overall, neuropathy outcomes varied in our cohort. For most, CIPN20 scores were stable to improved between T3 and T4, yet 3 participants (mean age 68.7) reported persistent numbness and tingling in their feet and toes. Increasing age has been reported as a risk factor for development of chemotherapy induced neuropathy with one study reporting persistence of symptoms in the post-treatment phase (Bulls et al., 2019; Hershman et al., 2016)."

Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Pain

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States (ASH 2025) - "Treatment regimens were categorized into 7 mutually exclusive groups: bendamustine (B)-based chemotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without cytarabine), Bruton tyrosine kinase inhibitors (BTKi; covalent: zanubrutinib, acalabrutinib, ibrutinib, and non-covalent: pirtobrutinib), bortezomib (bort)-based, venetoclax (ven)-based, intensive chemotherapy (high-dose cytarabine, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, etc.), and other regimens (CAR-T or others). However, chemotherapy and/or immunotherapy were associated with the highest HCRU while BTKi were associated with the lowest HCRU. Notably, more than half of patients previously treated with BTKi and anti-CD20 therapies were subsequently treated with another covalent BTKi or a non-covalent BTKi, while approximately one-third received chemotherapy and/or immunotherapy, further emphasizing the need for novel..."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Double trouble: The first reported case of evans syndrome following RSV Vaccination (ASH 2025) - "Her home medications included amlodipine, losartan, hydrochlorothiazide, and she reported receiving the RSV vaccine one week before admission...The patient was started on presumed ITP treatment with a 1g/kg dose of IVIG and high-dose dexamethasone 40 mg for 4 days...Due to refractory thrombocytopenia, the treatment was shifted to rituximab after the development of hemolytic anemia. The patient received a total of 4 doses weekly, along with a prednisone taper starting at 1 mg/kg, resulting in a slow improvement in her counts back to normal...Evans syndrome ideally requires multidisciplinary care and long-term monitoring due to its chronic, relapsing nature. This case highlights the importance of ongoing pharmacovigilance and educating physicians about immune-mediated hematologic complications that can occur post-vaccination, which are rare but potentially severe."

Clinical • Cardiovascular • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Primary Immunodeficiency • Respiratory Syncytial Virus Infections • Thrombocytopenia • HP

Feasibility assessment of indirect treatment comparison between off-label rituximab and novel treatments in patients with warm autoimmune hemolytic anemia (ASH 2025) - "Among the clinical trials included, five studied rituximab, in combination with prednisone, prednisolone, ibrutinib, or bortezomib. Three trials studied fostamatinib, while other studied treatments included pegcetacoplan, sovleplenib, parsaclisib, and rilzabrutinib...Future work should consider de novo sources of real-world evidence for rituximab that more closely align with registrational trial characteristics and endpoint definitions. However, aligning timing of endpoint measurements between registration trials and real-world data to match definitions remains challenging."

Clinical • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology

Validation of the boscore model for predicting invasive mold disease in Chinese patients with hematological malignancies undergoing chemotherapy: A single-center retrospective study (ASH 2025) - "Using the BOSCORE model, 7 risk factors were assessed: history of IMD, prednisone-equivalent ≥0.5mg/kg within 30 days, uncontrolled underlying malignancy, high-risk chemotherapy, absolute neutrophil count (ANC) 10 days, absolute lymphocyte count (ALC) <50/µl, and cytomegalovirus (CMV) infection... The BOSCORE model effectively distinguishes high- vs low-risk IMD in Chinese HM patients, with high-risk patients showing significantly higher IMD incidence. It performs particularly well in AL patients with chemotherapy-induced profound neutropenia. Validation in multi-center prospective studies is needed to confirm its utility, with potential subgroup analyses for AL and lymphoma to optimize risk stratification and targeted antifungal prophylaxis."

Retrospective data • Cytomegalovirus Infection • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Oncology

Clinical use of genome-wide hi-c sequencing for assessment of structural variants in diffuse large B-cell lymphoma (ASH 2025) - "The patient was treated with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) but subsequently progressed through therapy. Hi-C sequencing was able to define the partner of the IGH gene rearrangements to be an intergenic region of chromosome 10, revealing that this was likely not related to the pathogenesis in this case. Furthermore, Hi-C sequencing found copy number aberrations and a tandem amplification of CD79B , a key regulator in B-cell signaling. Accordingly, this finding is associated with a more aggressive phenotype in DLBCL, as was observed in this patient."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD79B • CLTC • IGH • MSI2 • PRKCA

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Large language models extract diverse manifestations of chronic GVHD from unstructured clinical documentation (ASH 2025) - "Of these patients, 58 were steroid refractory/dependent and received a second line immunosuppressant such as ruxolitinib (76% of patients), belumosudil (14%), or ibrutinib (16%). Presence of any non-scorable symptom (i.e. muscle symptom, nasal/sinus symptoms, serositis, or capillary leak syndrome) in the two weeks leading up to the start of corticosteroid therapy occurred more frequently in patients who required additional immunosuppression (11/58, 19.0%) compared those who received prednisone alone (6/85, 7.1%) with an odds ratio of 0.32 (pvalue 0.04)...This approach enabled the construction of a comprehensive database of events post-transplant. We anticipate that this database will facilitate future investigation into distinct patterns of cGVHD activity, creating well-calibrated metrics of disease severity, and predicting response to immunosuppressive therapy."

Clinical • Cardiovascular • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Otorhinolaryngology

Outcomes of stem cell transplantation in pediatric and adolescent/young adult patients with trisomy 21: A single-center experience (ASH 2025) - "All patients received a myeloablative conditioning with post-transplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis...One patient developed steroid refractory grade III skin GvHD requiring prednisone, ruxolitinib, and topical tacrolimus, and experienced eventual improvement with extracorporeal photopheresis... Here we describe three patients with T21 who underwent HSCT for relapsed/refractory leukemia. Two patients are surviving, including one with multiply relapsed disease who had initial graft failure, and remains disease free 2 years and 7 months following HSCT. Toxicities following HSCT were manageable and did not significantly impact engraftment."

Clinical • Acute Kidney Injury • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • CNS Disorders • Developmental Disorders • Endocrine Disorders • Epilepsy • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Nephrology • Pediatrics • Transplantation • TP53

GMP-compliant generation, expansion, and a preliminary safety evaluation of CMV-specific t cells using a closed system for post-transplant viral control (ASH 2025) - "His prior treatments included ABVD, DHAP, ICE, GVD, brentuximab vedotin (BV), autologous hematopoietic stem cell transplantation, and pembrolizumab, which led to complete remission...The post-transplant course was complicated by chronic graft-versus-host disease (overlap subtype), presenting with grade 3 skin and grade 2 oral involvement, which was managed with prednisone and tacrolimus. In early 2025, the patient developed CMV reactivation with a high viral load (>200,000 copies/mL) that proved refractory to ganciclovir, which was discontinued due to hematologic toxicity and the detection of viral resistance associated with an M460V mutation...These findings support further investigation of CMV-specific T cell therapy as a valuable adjunct in managing opportunistic infections in immunocompromised hosts. Funding: Ministry of Health of Brazil, SIPAR (NUP) 25000.156425/2023-06"

Clinical • Post-transplantation • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Classical Hodgkin Lymphoma • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Transplantation • IFNG • IL2 • IL7

Remission instead of eradication? MEK inhibition in primary refractory childhood LCH (ASH 2025) - "Patient and Methods We report on a 9-month-old infant with multisystemic LCH (thymus and cervical lymph nodes) who progressed under vinblastin/prednisone and did not respond to second-line cytarabine/vincristine therapy...This class confers resistance to first-and second generation BRAF inhibitors (e.g., Vemurafenib, Dabrafenib), which preferentially target monomeric BRAFV600E but not dimer-dependent BRAF. Functional ex vivo drug sensitivity profiling demonstarted superior tumor cell cytotoxicity of cobimetinib compared to other tested agents, including BRAF inhibitors and alternative MEK1/2 inhibitors, such as trametinib and selumetinib...However, the risk of clonal persistence underscores the need for integrated strategies. Future studies should investigate rational combinations of MEK inhibitors with senolytics and/or mTOR blockade to target both MAPK signaling and senescent cell survival, thereby suppressing SASP-related inflammation, aiming for durable molecular..."

Clinical • Hematological Malignancies • Langerhans Cell Histiocytosis • ARAF

Polatuzumab vedotin, zanubrutinib, rituximab, lenalidomide, and prednisone (Pola-ZR2P) as frontline immunochemotherapy in previously untreated DLBCL patients (ASH 2025) - P2 | "She had a history of arrhythmia managed with intermittent propafenone. Pola-ZR2P regimen demonstrated promising efficacy and a manageable safety profile in this cohort of previously untreated DLBCL patients. This report provides clinical evidence on the efficacy and safety of Pola-ZR2P regimen as the frontline immunochemotherapy in previously untreated DLBCL patients. Further enrollment of more patients is necessary to better clarify the effectiveness and safety of Pola-ZR2P regimen as the frontline chemotherapy in DLBCL patients."

Clinical • B Cell Lymphoma • Cardiovascular • Coronary Artery Disease • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastroenterology • Hematological Disorders • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pruritus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Septic Shock • TP53

Epcoritamab monotherapy provides superior efficacy vs non–anthracycline-containing regimens in newly diagnosed elderly DLBCL patients deemed unsuitable for anthracycline-containing regimens: A match-adjusted comparative efficacy analysis (ASH 2025) - P2 | "Non-AC CITs included rituximab (R)-cyclophosphamide, doxorubicin, vincristine, prednisone [R-CEOP]/R-cyclophosphamide, vincristine, prednisone [R-CVP]/R-cyclophosphamide, etoposide, prednisone, procarbazine [R-CEPP]), bendamustine and rituximab (BR), and other combination regimens. Fixed-duration epcor mono demonstrated significantly superior OS vs non-AC regimens in newly diagnosed elderly and/or frail DLBCL pts deemed unsuitable for anthracyclines. These findings support epcor mono as a potential 1L chemo-free treatment option for newly diagnosed DLBCL pts unsuitable for AC regimens."

Clinical • Monotherapy • Diffuse Large B Cell Lymphoma • Large B Cell Lymphoma • Palliative care

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China (ASH 2025) - "Introduction: The landmark POLARIX study showed that Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) regimen was superior to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) in previously untreated diffuse large B-cell lymphoma (DLBCL) with IPI 2-5. This investigation represents the first multicenter study addressing real-world outcomes of IPI 0-1 DLBCL patients treated with first-line Pola-R-CHP. Our results suggested that Pola-R-CHP showed excellent effectiveness and manageable toxicities for this specific population, even among those with adverse risk factors."

Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • TP53

Tolerability and long-term survival of fragile or older patients with diffuse large B cell lymphoma (DLBCL) not otherwise specified by R-CDOP (ASH 2025) - "The regimen included Rituximab 375mg/m2, Cyclophosphamide 750mg/m2, liposomal doxorubicin 30mg/m2 on day 1 and prednisone 100mg day 1-5, every 21 days a cycle, followed by granulocyte colony stimulating factor and preventive antibiotics support. RCDOP as frontline appears tolerable for olderly with DLBCL NOS and gives durable response and long-term survival."

Clinical • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Effectiveness and safety profile of pola-based regimen in DLBCL Patients with high-risk factors in real world: A retrospective study in China (ASH 2025) - "Background Polatuzumab vedotin, an antibody-drug conjugate targeting CD79b, has become the standard of care (SOC) for both treatment-naive (TN) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients, administered via the Pola-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) and Pola-BR (bendamustine plus rituximab) regimens. Even in this high-risk population, Pola-based therapy demonstrated promising efficacy and manageable toxicity. However, detailed data on response rates and survival outcomes require further reporting following extended follow-up."

IO biomarker • Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma • CD5 • CD79B • TP53

Real-world efficacy and safety of pomalidomide-rituximab-based combination therapy in newly diagnosed extranodal diffuse large B-cell lymphoma (ASH 2025) - "Introduction The R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone) has been established as the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) in clinical practice...Pomalidomide, a third-generation immunomodulatory agent, exhibits more potent immunomodulatory effects compared to lenalidomide...Pomalidomide-rituximab was combined with CHOP-like regimens (n = 10), bendamustine (n = 1), brentuximab vedotin (n = 1), or BTK inhibitors (n = 2)...Grade 3-4 non-hematological AEs occurred in four patients, including one with hyponatremia and three with infections. Conclusion This real-world analysis demonstrated that the pomalidomide-rituximab-based combination therapy had promising efficacy, with a high ORR of 92.9%, in treatment-naïve DLBCL patients with extranodal disease, and exhibited acceptable hematological toxicity."

Clinical • Combination therapy • Real-world • Real-world effectiveness • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Heart Failure • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rare Diseases • Thrombocytopenia • CD5 • TP53

Utilization and tolerability of R-CHOP and R-mini–CHOP in patients with diffuse large B-cell lymphoma (DLBCL) at a community cancer center (ASH 2025) - "Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard therapy for patients diagnosed with DLBCL. R-CHOP was associated with high treatment completion and with toxicity, however there was no statistical significance in toxicities or relapse rates noted when compared to R-mini-CHOP. The underutilization of R-mini-CHOP along with significant loss to follow-up in the untreated group limited comparative assessment. These findings underscore the need for quality initiatives to expand appropriate use of R-mini-CHOP and strengthen longitudinal follow-up in community oncology settings."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study (ASH 2025) - "Treatment regimens included Pola-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in 30 patients, Pola-miniCHP in 4 patients, Pola-ZR (zanubrutinib, rituximab) in 6 patients, and other regimens in 2 patients. Dose-reduced chemoimmunotherapy (Pola-miniCHP) and chemo-light regimens (Pola-ZR) provided reasonable efficacy in elderly or frail patients, warranting further evaluation in larger cohorts. Keywords polatuzumab vedotin; diffuse large B-cell lymphoma; newly diagnosed; efficacy; safety"

Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Geriatric Disorders • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases

A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China (ASH 2025) - "Polatuzumab vedotin, an anti-CD79b monoclonal antibody, when combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), offers the benefits of more convenient administration and comparable safety to the R- CHOP regimen, while demonstrating reduced toxicity comparison to DA-EPOCH-R...Another patient attained CMR following R-ESHAP treatment for lymph node relapse, whereas one succumbed to CNS relapse despite receiving multiple therapies, including surgery, HD-MTX BV, selinexor, and thiotepa.5 patients received targeted therapies...Summary/Conclusion POLA-R-CHP shows potential as an efficient therapy for PMBCL. Its frontline application could enhance overall response rates while reducing treatment-related toxicity."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Renal Disease • Respiratory Diseases • CD79B

Polatuzumab-vedotin in large diffuse B-cell lymphoma: A multicenter observational study from Latin America (2020–2024) (ASH 2025) - "Introduction: Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug conjugate linked to monomethyl auristatin E (MMAE), demonstrated improved progression-free survival (PFS) in the phase 3 POLARIX trial when combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with R-CHOP in the frontline treatment of diffuse large B-cell lymphoma (DLBCL) (Sehn et al., 2022). To our knowledge, this is one of the first real-world analyses of polatuzumab vedotin (Pola)-based regimens in Latin America. In a resource-constrained setting with heterogeneous treatment strategies, Pola demonstrated meaningful clinical activity across multiple lines of therapy. Response rates and 1-year overall survival were comparable to those reported in the phase 2 trial by (Sehn et al.,2022) and exceeded outcomes from other real-world cohorts in relapsed/refractory DLBCL."

Clinical • IO biomarker • Observational data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2 • BCL6 • CD79B • TP53